Abbott's Proclaim XR Neurostimulation Implant Device Said to Reduce Pain

At the 2020 North American Neuromodulation Society annual meeting, Abbott (NYSE: ABT) reported data from a clinical trial testing its Proclaim XR neurostimulation implant in patients with chronic pain. The system was able to reduce pain catastrophizing scale scores (PCS), which measures the psychological aspects of pain, by an average of 62%.

Using another measure for pain, the Oswestry Disability Index (ODI), 78% of patients had a score of "severe," "crippling," or "bed bound," at the start of the study, which was reduced to just 29% of patients after six months of having the implant -- with none of the patients reported as "bed bound." At the other end of the scale, 71% of people in the clinical trial had a minimal or moderate ODI score after six months of using the Proclaim XR.

Image source: Getty Images.

Continue reading

Source Fool.com